Bismuth-norfloxacin complex: Synthesis, physicochemical and antimicrobial evaluation

Aldrich Catalogue, 2001. p. 211. Bland, 2004, The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation, Antimicrob. Agents Chemother., 48, 1983, 10.1128/AAC.48.6.1983-1988.2004 Bolton, 2001 Borrel, 1997, Calculating microspecies concentration of zwitterion amphoteric compounds: ciprofloxacin as example, Chem. Educ., 47, 1311, 10.1021/ed074p1311 Bukovec, 1997, Crystal structure of ciprofloxacin hexahydrate and its characterization, Int. J. Pharm., 152, 59, 10.1016/S0378-5173(97)04913-2 Clitherow, J., 1991. Salts of ranitidine and complexes of bismuth with carboxylic acids, and pharmaceutical compositions thereof. US Patent Number 5,008,256. Domenico, 1996, Resistance to bismuth among Gram-negative bacteria is dependent upon iron and its uptake, Antimicrob. Agents Chemother., 38, 1031, 10.1093/jac/38.6.1031 Furet, 1992, Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients, Antimicrob. Agents Chemother., 36, 2506, 10.1128/AAC.36.11.2506 Gao, 1995, Synthesis, characterization and antibacterial activity of novel Fe(III), Co(II), and Zn(II) complexes with norfloxacin, J. Inorg. Biochem., 60, 61, 10.1016/0162-0134(95)00002-6 Indian Pharmacopoeia, 1996. Microbiological Assay of Antibiotics, 3rd ed. Published by Controller of Publications, Government of India, A-144. Kawai, 1996, Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats, Chem. Pharm. Bull., 44, 1425, 10.1248/cpb.44.1425 Leban, 1997, Crystal structure and characterization of the bismuth (III) compound with quinolone family member (ciprofloxacin). Antibacterial study, J. Inorg. Biochem., 66, 241, 10.1016/S0162-0134(96)00218-8 Ma, 1997, Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations, Pharm. Res., 14, 366, 10.1023/A:1012014608733 National Committee for Clinical Laboratory Standards, 1993. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 3rd ed. Approved Standard. NCCLS Document M11-A3, National Committee for Clinical Laboratory Standards, Wayne, PA, p. 13, 26. Naumann, 1989, Fluoroquinolones-antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs, Internist (Berl.), 30, 20 Peter, 2005, Treatment of Helicobacter pylori, Helicobacter, 10, 40, 10.1111/j.1523-5378.2005.00333.x 1993, 145 Sharma, 2003, Zinc-naproxem complex: physicochemical and biological evaluation, Int. J. Pharm., 260, 217, 10.1016/S0378-5173(03)00251-5 Shen, 1985, Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA, Proc. Natl. Acad. Sci., 82, 307, 10.1073/pnas.82.2.307 Shen, 1989, Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme–DNA complexes, J. Biol. Chem., 264, 2973, 10.1016/S0021-9258(19)81708-8 Shen, 1989, Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model, Biochemistry, 28, 3886, 10.1021/bi00435a039 Takahata, 1988, DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity, Antimicrob. Agents Chemother., 32, 1192, 10.1128/AAC.32.8.1192 Turel, 1996, Synthesis, crystal structure, and characterization of three novel compounds of the quinolone family member (norfloxacin), J. Inorg. Biochem., 61, 197, 10.1016/0162-0134(95)00056-9 Turel, 1994, Synthesis, characterization, and crystal structure of a copper (II) complex with quinolone family member (ciprofloxacin): bis(1)-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylate) copper (II) chloride hexahydrate, J. Inorg. Biochem., 56, 273, 10.1016/0162-0134(94)85107-7 United States Pharmacopoeia 25 and National Formulary 20, 2002. Microbiological Tests. United States Pharmacopoeia Convention, Inc., pp. 1883–1889. Willard, 1986 Zupan, 2001, Synthesis and characterization of two novel zinc (II) complexes with ciprofloxacin. Crystal structure of C17H19N3O3F2 ZnCl4·2H2O, Crotica Chemica Acta, 74, 61